MRNS - Marinus Pharmaceuticals Inc
IEX Last Trade
1.42
0.020 1.408%
Share volume: 414,734
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$1.40
0.02
1.43%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-07 | 2023-03-09 | 2023-05-11 | 2023-08-10 | 2023-11-07 | 2024-03-05 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 109.377 M | 184.841 M | 259.518 M | 226.817 M | 201.200 M | 200.806 M | 170.908 M | 137.350 M | |
| Current Assets | 101.091 M | 177.006 M | 252.378 M | 219.995 M | 194.609 M | 195.040 M | 165.246 M | 131.276 M | |
| Inventories | 0.000 | 104.000 K | 77.000 K | 37.000 K | 2.674 M | 2.736 M | 2.413 M | 5.783 M | |
| Other Current Assets | 5.765 M | 5.255 M | 5.402 M | 9.064 M | 11.365 M | 11.667 M | 8.746 M | 8.727 M | |
| Short Term Investments | 5.765 M | 5.255 M | 5.402 M | 9.064 M | 11.365 M | 11.667 M | 8.746 M | 8.727 M | |
| Total Receivables | 3.000 M | 3.398 M | 6.348 M | 11.693 M | 5.234 M | 4.281 M | 3.799 M | 3.513 M | |
| Current Cash | 92.326 M | 168.249 M | 240.551 M | 199.201 M | 175.336 M | 176.356 M | 150.288 M | 113.253 M | |
| Total Non-current Assets | 8.286 M | 7.835 M | 7.140 M | 6.822 M | 6.591 M | 5.766 M | 5.662 M | 6.074 M | |
| Property Plant Equipment | 5.561 M | 5.520 M | 4.236 M | 4.037 M | 3.938 M | 3.909 M | 3.843 M | 3.735 M | |
| Other Assets | 2.725 M | 2.315 M | 2.904 M | 2.785 M | 2.653 M | 1.857 M | 1.819 M | 2.339 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 109.377 M | 184.841 M | 259.518 M | 226.817 M | 201.200 M | 200.806 M | 170.908 M | 137.350 M | |
| Total liabilities | 104.574 M | 102.837 M | 143.518 M | 141.732 M | 143.861 M | 146.269 M | 154.143 M | 153.784 M | |
| Total current liabilities | 23.110 M | 21.050 M | 25.017 M | 21.514 M | 25.603 M | 30.555 M | 40.624 M | 42.758 M | |
| Accounts Payable | 3.299 M | 1.622 M | 4.461 M | 4.466 M | 2.302 M | 2.626 M | 4.003 M | 6.125 M | |
| Other liabilities | 11.114 M | 11.007 M | 17.626 M | 17.827 M | 18.172 M | 18.076 M | 18.330 M | 18.312 M | |
| Current long term debt | 0.000 | 0.000 | 1.020 M | 1.321 M | 5.406 M | 9.601 M | 13.762 M | 17.912 M | |
| Long term debt | 70.350 M | 70.780 M | 100.875 M | 102.391 M | 100.086 M | 97.638 M | 95.189 M | 92.714 M | |
| Other liabilities | 11.114 M | 11.007 M | 17.626 M | 17.827 M | 18.172 M | 18.076 M | 18.330 M | 18.312 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 4.803 M | 82.004 M | 116.000 M | 85.085 M | 57.339 M | 54.537 M | 16.765 M | -16.434 M | |
| Common stock | 37.156 M | 37.202 M | 45.042 M | 51.770 M | 52.552 M | 53.920 M | 56.744 M | 56.852 M | |
| Retained earnings | -469.499 M | -396.209 M | -430.521 M | -465.251 M | -497.185 M | -530.157 M | -571.926 M | -610.595 M |